Neuland Laboratories

Neuland Laboratories Operating Cash Flow

The Operating Cash Flow of Neuland Laboratories (NEULANDLAB.NS) as of Nov 19, 2026 is 3.38 B INR. In the previous year, Operating Cash Flow was 3.17 B INR — a change of 6.57% (higher).

Operating Cash Flow

3.38 BINR

YoY

6.57%

Last updated:

Operating Cash Flow of Neuland Laboratories is 2026 3.38 B INR. Operating Cash Flow of Neuland Laboratories was 2025 3.17 B INR. It decreases by 6.57% higher compared to the previous year.

The Neuland Laboratories Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2019
699.07 M INR
Jan 1, 2020
573.41 M INR
Jan 1, 2021
1.89 B INR
Jan 1, 2022
585.81 M INR
Jan 1, 2023
2.39 B INR
Jan 1, 2024
2.56 B INR
Jan 1, 2025
3.17 B INR
Jan 1, 2026
3.38 B INR
The Neuland Laboratories Operating Cash Flow history
YEAROperating Cash FlowYoY
3.38 BINR+6.57%
3.17 BINR+24.13%
2.56 BINR+7.19%
2.39 BINR+307.19%
585.81 MINR-69.06%
1.89 BINR+230.24%
573.41 MINR-17.98%
699.07 MINR+520.41%
112.68 MINR-70.87%
386.81 MINR-13.71%
448.27 MINR+240.31%
131.72 MINR-70.32%
443.82 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuland Laboratories stock

Operating Cash Flow of Neuland Laboratories is 3.38 B INR in 2026.

Operating Cash Flow of Neuland Laboratories changed from 3.17 B INR to 3.38 B INR, representing a 6.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Neuland Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Neuland Laboratories

All Key Metrics — Neuland Laboratories